---
document_datetime: 2026-02-06 09:29:11
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xerava-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xerava-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4655064
conversion_datetime: 2026-02-09 21:59:47.621845
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xerava

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 13/11/2025                          | 18/12/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Xerava-H-C- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000265697                     | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of complicated intra-abdominal infections (cIAI) from the age of 12 years weighing at least 50 kg for XERAVA, based on final results from study TP-434-028; this is a phase 1, open-label, multicenter study to determine the pharmacokinetics and safety of intravenous eravacycline in children with suspected or confirmed bacterial infection. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with   |            |     | 004237-VR/0000265697'   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------|
| Variation type IA / EMA/VR/0000308231 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/10/2025 | N/A |                         |
| Variation type IB / EMA/VR/0000285584 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/07/2025 | N/A |                         |

<div style=\"page-break-after: always\"></div>

| B.I.c.1 Change in immediate packaging of the active substance - B.I.c.1.a Qualitative and/or quantitative composition - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | specified in the technical dossier) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / | This was an application for a group of variations. B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.c Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.a | 17/02/2025 | N/A | EMA/VR/0000252170 |